Kinoxis Therapeutics: Funding, Investors & Team (Oct 2026)
Kinoxis Therapeutics, an emerging biotechnology company located in Australia, is focused on advancing the development of innovative therapeutic compounds for substance use disorders and other conditions affecting the central nervous system. The company has acquired the rights to these compounds from the University of Sydney, with the primary candidate showing promising effects in various animal studies and is currently undergoing preclinical trials.
Kinoxis Therapeutics has raised $14.4M across 2 funding rounds on record, the most recent an undisclosed round of $4.8M announced in Sep 2026.
That round is below the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Kinoxis Therapeutics Company Profile and Key Stats
Latest funding round on record: Sep 2026.
Kinoxis Therapeutics Funding Rounds
Kinoxis Therapeutics raised $9.6M in a Series B announced in Aug 2024.
2.1 years later, an undisclosed round of $4.8M was announced in Sep 2026.
Kinoxis Therapeutics Investors
9 investors are recorded in total; the 5 named above are those the record identifies.
Kinoxis Therapeutics Founders and Leadership Team
Contact details for the Kinoxis Therapeutics team: 2 of 2 have an email address on file, 1 has a LinkedIn profile.
Start 14-day free trial →Kinoxis Therapeutics Funding Compared to Other Biotechnology Startups
Kinoxis Therapeutics' latest round of $4.8M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Kinoxis Therapeutics in Biotechnology and Melbourne
Companies Similar to Kinoxis Therapeutics
AdvanCell is a company that focuses on developing innovative cancer treatments using alpha-emitting isotopes…
The objective of Fluent is to seamlessly integrate humans with AI, improving interaction and communication…
Mesoblast is a developer of biologic products for the broad field of regenerative medicine. Mesoblast's…
Microba Life Sciences Ltd. provides consumers, doctors, and researchers with gut microbiome testing services…
Algenie was founded on a simple realization: algae has the potential to save the earth, but only if it is…
Paradigm Pharmaceuticals is a global biopharmaceutical company driven to discover, develop, and deliver…
Imugene is a publicly-listed biotechnology company with operations in America and Europe,
BiomeBank’s mission is to treat and prevent disease by restoring gut microbial ecology
Telix Pharmaceuticals Ltd is a clinical-stage biotechnology company engaged in developing and commercializing…
Cauldron Ferm is a technique that speeds up the production of precision fermented prototypes to commercial…
HydGene Renewables is developing a biotechnology platform that produces on-site green hydrogen from waste…
Swan Genomics is focused on commercialising an innovative new approach to DNA sequencing to deliver more…
Kinoxis Therapeutics Funding FAQs
What does Kinoxis Therapeutics do?
Kinoxis Therapeutics, an emerging biotechnology company located in Australia, is focused on advancing the development of innovative therapeutic compounds for substance use disorders and other conditions affecting the central nervous system. The company has acquired the rights to these compounds from the University of Sydney, with the primary candidate showing promising effects in various animal studies and is currently undergoing preclinical trials.
How much funding has Kinoxis Therapeutics raised?
Kinoxis Therapeutics has raised $14.4M across 2 rounds on record. The most recent is an undisclosed round of $4.8M announced in Sep 2026.
When did Kinoxis Therapeutics last raise funding?
Kinoxis Therapeutics' most recent funding round on record is an undisclosed round of $4.8M, announced in Sep 2026.
Who has invested in Kinoxis Therapeutics?
Investors on record for Kinoxis Therapeutics include Main Sequence Ventures, National Institutes of Health, Uniseed, University of Sydney, Stoic VC. FundedIQ records 9 investors in total.
Who founded Kinoxis Therapeutics?
FundedIQ lists Michael Bowen (Founder) at Kinoxis Therapeutics.
Who is the CEO of Kinoxis Therapeutics?
Hugh Alsop is listed as Chief Executive Officer at Kinoxis Therapeutics.
Where is Kinoxis Therapeutics headquartered?
Kinoxis Therapeutics is based in Melbourne, Victoria, Australia.
How many employees does Kinoxis Therapeutics have?
Kinoxis Therapeutics is in the 11-50 employee band.
When was Kinoxis Therapeutics founded?
Kinoxis Therapeutics was founded in 2017.
How does Kinoxis Therapeutics' funding compare to other Biotechnology startups?
Kinoxis Therapeutics' latest round of $4.8M is below the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Kinoxis Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Kinoxis Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.